NurPhoto via Getty Images
According to the target date announced by the Centers for Disease Control and Prevention on Friday, states should work hard to prepare to distribute the COVID-19 vaccine by November 15.
So far, this is an encouraging day-there is still no approved vaccine, and it may have to wait until later this year or later. However, in preparation for the day, a group of the CDC’s Immunization Practice Advisory Committee (mainly composed of doctors and public health experts outside the CDC) met on Friday to discuss how to best distribute this Plant a vaccine, and weighed who will rank first.
Once the US Food and Drug Administration (CODID) has approved the COVID-19 vaccine, ACIP will make recommendations on how to use the vaccine. Paul Mango, chief official of the Ministry of Health and Human Services, said its guidelines will trigger the start of the vaccine distribution process.
“[The government] We plan to distribute the vaccine within 24 hours after the final approval of ACIP. Mango told reporters at a press conference on October 23.
In ACIP At the Friday meeting, members reviewed the current known knowledge about candidate vaccines in clinical trials and laid the foundation so that once the vaccine is approved, they can quickly make a decision.
In an introduction to the committee, Dr. Mary Chamberland of the Centers for Disease Control and Prevention (CDC) said that ACIP has agreed to follow to maximize benefits, minimize harm, promote justice and reduce health problems when determining early allocation groups. The principle of equality.
ACIP discussed four overlapping groups of people who are most likely to be at high risk of COVID-19, and these risks may be a priority for getting a vaccine. The consultants said that the timetable for when to vaccinate depends on the characteristics of the vaccine and the quantity available.
Nonetheless, there has been a consensus that, given that medical staff have a high risk of exposure, they should get the vaccine first. ACIP defines health care workers as “paid and unpaid people who serve in the health care environment and may have direct or indirect contact with patients or infectious materials.” The population is estimated at 21 million.
The second group outlined by ACIP will be much larger, 87 million. This will include workers in other basic fields, who are defined as “operating in operations critical to the continued critical infrastructure, such as food, agriculture, transportation, education, and law enforcement”.
The third group of people is about 100 million, and their health conditions make people more susceptible to severe COVID-19 disease. These adults suffer from one or more high-risk medical conditions, such as obesity, diabetes, and cardiovascular disease.
The fourth group of people who can be given priority for vaccination is adults 65 years and older (53 million people). They have no other health conditions, but are at risk of serious diseases based on their age. The CDC says this includes adults living at home and adults (3 million) living in long-term care facilities.
ACIP’s goal is to use vaccines to reduce the spread, illness and death of COVID-19, and different strategies are currently being considered to achieve this goal.
To this end, a model study conducted by Matthew Biggerstaff, an epidemiologist at the Centers for Disease Control and Prevention (CDC), shows that in the United States, first vaccinating all adults 65 years and older (after health care workers) may reduce the risk of Of total deaths have the greatest impact
Biggerstaff’s speech also suggested that vaccinating high-risk adults of any age with underlying diseases (such as lung disease, heart disease, diabetes, kidney disease or obesity) may have the greatest effect on reducing the number of infections, thereby limiting transmission Coronavirus.
Biggerstaff cautions that these are only theoretical situations, and actual results may vary, depending on the characteristics of each available vaccine.
Dr. Janell Routh, a medical staff member of the CDC, told the committee that states and territories are working to set the “preparation date” for vaccine distribution to November 15. She said: “We want to make sure that everything can be accepted and managed before the product is launched.”
64 jurisdictions, including states, territories and some large cities, have submitted preliminary plans for the distribution of vaccines to the CDC. The Centers for Disease Control and Prevention (CDC) provided feedback on the plan this week and hopes that states will recruit medical service providers, establish data systems to track who is vaccinating, and cooperate with community leaders, so states are ready Vaccines will be issued immediately after obtaining vaccine authorization. FDA.
Routh said plans are also being developed to increase the state’s ability to distribute vaccines in long-term care facilities through the Federal Pharmacy Partnership. A revised “playbook” was released on Friday for states to use when formulating plans, noting that these partners may include national chains, large regional chains, or independent pharmacy networks. Routh said that 55% of qualified US pharmacies have signed up for COVID-19 injections.
After the vaccine is approved, the Centers for Disease Control and Prevention will plan to launch a nationwide “Vaccination with Confidence” campaign and promote it to health care providers and communities to encourage people to get the vaccine. Dr. Amanda Cohn, acting chief medical officer of CDC’s vaccine policy, said the public health campaign will be based on “evidence-based content to amplify the information that enables individuals to decide to vaccinate.”
The team also listened to data on research progress from Novavax and Janssen, two candidate vaccine manufacturers, which are still recruiting volunteers. It is uncertain whether these two vaccines will be released first.
Approved by the FDA or given emergency authorization for any vaccine. In the United States, there are currently four candidate vaccines in the final stages of clinical research. So far, no company has applied for authorization or approval from the FDA.